News >

O'Regan Shares Insight on Biosimilar Revolution in Oncology

Ellie Leick
Published: Wednesday, Feb 19, 2020

Ruth O'Regan, MD, professor of medicine, Division of Hematology/Oncology, at University of Wisconsin School of Medicine and Public Health, associate director, Clinical Research, University of Wisconsin Carbone Cancer Center

Ruth O'Regan, MD

Biosimilars continue to emerge in oncology, leading to treatment options at significant discounts compared with their reference products, explained Ruth O’Regan, MD.

“A huge issue in this country and worldwide is that all of these drugs are so expensive. As a community, we need to find a way of dropping the price of these drugs. The data with the biosimilars show, very clearly, that they are similar in efficacy and toxicity of the parent drug,” said O’Regan. “If [biosimilars] are cheaper, we should use them.”

Currently, there are 5 trastuzumab (Herceptin) biosimilars with FDA-approved indications for patients with HER2-positive breast cancer or metastatic gastric or gastroesophageal junction adenocarcinoma: MYL-1401O (Ogivri; trastuzumab-dkst), CT-P6 (Herzuma; trastuzumab-pkrb), SB3 (Ontruzant; trastuzumab-dttb), PF-05280014 (Trazimera; trastuzumab-qyyp), and ABP 980 (Kanjinti; trastuzumab-anns).

... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication